跳至主要内容
临床试验/ACTRN12619000644167
ACTRN12619000644167招募中未知

Randomised controlled trial (RCT) examining the effect of ROTEM-guided blood component administration versus standard of care on blood component transfusion requirements and complications in patients with cirrhosis and coagulopathy undergoing invasive procedures

Alfred Health0 个研究点目标入组 50 人开始时间: 2019年4月30日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
Alfred Health
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Males and females aged 18 years or older
  • -Cirrhosis
  • -Planned for an invasive procedure
  • -Coagulopathic on the basis of conventional coagulation tests
  • -Able to give informed consent

排除标准

  • -Persons under 18 years of age
  • -Inability or unwillingness to give informed consent
  • -Coagulation disorders (other than those relating to liver disease)
  • -Patients on anticoagulant medications (e.g. warfarin, enoxaparin, rivaroxaban, dabigatran, apixiban).
  • -Patients on anti-platelet aggregation agents other than aspirin (eg. clopidogrel, ticagrelor)
  • -Patients in whom it is difficult to obtain blood samples due to venous access difficulties
  • -Active malignancy
  • -Patients who have received FFP, platelet transfusion, cryoprecipitate in the week prior
  • - Patients with stage 4 or 5 chronic kidney disease
  • -Patients receiving renal replacement therapy
  • -Patients with active sepsis

研究者

发起方
Alfred Health

相似试验